Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Pancreatic Cancer

 

Temozolomide and Pazopanib Hydrochloride for Pancreatic Cancer
A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)

Investigator: Gabriela Chiorean, MD;   Conditions: Pancreatic Cancer;    Status: Pending;   Study ID: NCT01465659

PRI-724 Plus Gemcitabine for Advanced or Metastatic Pancreatic Adenocarcinoma (20141153)
Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination with Continuous Intravenous Doses of PRI-724, a CBP/ B-Catenin Inhibitor, to Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy after Failing First-Line Therapy with FOLFIRINOX (or FOLFOX)

Investigator: Elena Chiorean;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01764477

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Closed;   Study ID: NCT01988896

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone for Patients With Resected Pancreatic Cancer (20140859)
A Phase 3, Multicenter, Open-label, Randomized Study of nabĀ®-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Investigator: Gabriela Chiorean;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01964430

Ruxolitinib for Advanced or Metastatic Pancreatic Cancer (20141052)
A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)

Investigator: Gabriela Chiorean;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT02117479